SK Bioscience
SK Bioscience Co Ltd is a South Korean biopharmaceutical enterprise headquartered in Seongnam, South Korea. The company specializes in the research, development, contract manufacturing, and commercialization of vaccines and biological therapies. Its product line encompasses proprietary vaccines for influenza, chickenpox, and shingles alongside contract manufacturing services for international pharmaceutical partners. Revenue is generated from product sales of commercialized vaccines, manufacturing service contracts, and technology licensing fees. The enterprise targets public health agencies, clinical networks, and international pharmaceutical markets. SK Bioscience Co Ltd is publicly listed on the Korea Exchange.
4 of the funds FundTelligence covers report a position in SK Bioscience.
- Legal name
- SK Bioscience Co Ltd
- Sector
- Health Care
- Country
- South Korea
- Funds holding it
- 4
Funds holding SK Bioscience
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.07 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)
- Storebrand Indeks Nye Markeder — Storebrand · 0.0 % (full portfolio disclosed, October 2026)
- Storebrand Emerging Markets — Storebrand · 0.0 % (full portfolio disclosed, October 2026)